---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-275674"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:05:46.164530+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Soleno initiates $100M accelerated share repurchase; amends loan facility

## Summary
- Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.
- Repurchase expected to complete in Q1 2026; final shares based on VWAP less discount.
- Amended Oxford loan facility to permit ASR; $50M committed Term C/D loans removed; remaining $100M uncommitted.
- CEO cites Q3 2025 profitability and confidence in VYKAT XR launch as rationale for buyback.

## SEC filing metadata
- accession: 0001193125-25-275674
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/0001193125-25-275674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/d63564d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-275674
- JSON: https://secwatch.observer/filing/0001193125-25-275674.json
- Plain text: https://secwatch.observer/filing/0001193125-25-275674.txt

## Key facts
- Debt Financings
  SOLENO THERAPEUTICS INC amended credit facility of $100.0 million with Oxford Finance LLC.
  - Instrument: credit facility
  - Principal: $100.0 million
  - Counterparty: Oxford Finance LLC
  - Event: amendment
  source text: the remaining $100.0 million of loans under the Loan Agreement is uncommitted and may be made available only upon the mutual agreement of the Company and the Lenders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/0001193125-25-275674-index.htm
- Debt Financings
  SOLENO THERAPEUTICS INC incurred senior notes of $100.0 million with Jefferies LLC.
  - Instrument: senior notes
  - Principal: $100.0 million
  - Counterparty: Jefferies LLC
  - Event: incurrence
  source text: (the “ Company ”) entered into a confirmation and a supplemental confirmation (together, the “ ASR Agreement ”) of an accelerated share repurchase transaction with Jefferies LLC (the “ Dealer ”). Under the ASR Agreement, the Company shall repurchase an aggregate of $100.0 million of the Company’s common stock, $0.001 par value per share (the “ Common Stock ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1484565/000119312525275674/0001193125-25-275674-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.